A Randomized, Placebo‐Controlled, Double‐Blind Phase III Trial Investigating the Efficacy and Safety of IncobotulinumtoxinA in the Treatment of Glabellar Frown Lines Using a Stringent Composite Endpoint
Pharmacology, Toxicology and Pharmaceutical Science
2
3%
Nursing and Health Professions
2
3%
Neuroscience
2
3%
Other
1
2%
Unknown
20
32%
Attention Score in Context
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 06 September 2013.
All research outputs
#20,653,708
of 25,371,288 outputs
Outputs from Dermatologic Surgery
#2,316
of 3,065 outputs
Outputs of similar age
#171,397
of 222,533 outputs
Outputs of similar age from Dermatologic Surgery
#33
of 53 outputs
Altmetric has tracked 25,371,288 research outputs across all sources so far. This one is in the 10th percentile – i.e., 10% of other outputs scored the same or lower than it.
So far Altmetric has tracked 3,065 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 7.6. This one is in the 10th percentile – i.e., 10% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 222,533 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 11th percentile – i.e., 11% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 53 others from the same source and published within six weeks on either side of this one. This one is in the 20th percentile – i.e., 20% of its contemporaries scored the same or lower than it.
